Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2025-05-02 M&A Activity
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
M&A Activity 2025
M&A Activity Classification · 99% confidence The document announces a strategic business development: a co-promotion agreement between ALK and ARS Pharma regarding the drug *neffy*® in the USA. It details the terms, financial implications (cost-sharing, revenue sharing), and impact on the company's operations and outlook. This type of announcement, detailing a significant commercial partnership, financing structure change, or strategic alliance that impacts future revenue/operations, best fits the 'Capital/Financing Update' (CAP) or potentially 'Regulatory Filings' (RNS) if it were a mandatory disclosure. However, since it explicitly discusses revenue sharing, cost structures, and strategic market access expansion, it is most closely aligned with a significant business/financing event. Given the options, 'CAP' (Capital/Financing Update) covers strategic financial arrangements, although 'RNS' (Regulatory Filings) is a common catch-all for material non-standard announcements. Since the core of the document is the financial structure of the deal (cost sharing, revenue share eligibility), CAP is a strong candidate. If the document were purely about a merger or takeover, TAR would apply. Since it is a partnership with financial terms, CAP is selected over the generic RNS.
2025-05-02 English
Earnings Release 2025
Earnings Release Classification · 99% confidence The document announces a strategic co-promotion agreement between ALK and ARS Pharma regarding the drug *neffy®* in the USA. It details the terms, financial structure (cost-sharing, revenue sharing), operational responsibilities, and the impact on ALK's US sales force and future revenue expectations. This type of announcement, detailing a significant business transaction, partnership, or strategic development that impacts financing or operations, fits best under the 'Capital/Financing Update' (CAP) if it involves raising capital or major debt restructuring, or 'Regulatory Filings' (RNS) if it's a general market announcement. Since this is a major commercial agreement (co-promotion/licensing expansion) that has financial implications but is not a standard financial report (like 10-K, ER, IR), and it is not explicitly about insider trading (DIRS), M&A (TAR), or dividend changes (DIV), it is a significant corporate event announcement. Given the options, 'Capital/Financing Update' (CAP) is plausible due to the revenue/cost sharing structure, but 'Regulatory Filings' (RNS) serves as a strong general category for material, non-standard corporate news releases that are not explicitly covered elsewhere. However, looking closely at the definitions, this is a strategic partnership announcement. It is not a standard earnings release (ER), interim report (IR), or a formal M&A (TAR). It is a material business development. In many filing systems, major commercial agreements fall under general disclosure or regulatory news. Since the document is a press release announcing a business deal with financial terms, and it doesn't fit the highly specific categories like DIRS, DIV, or M&A, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for a material corporate press release that isn't a formal financial statement or proxy material. The document length (4689 chars) is substantial enough to be the primary announcement, not just a link to a report (ruling out RPA). FY 2025
2025-05-02 Danish
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document is a press release from ALK announcing that health authorities in 17 EU countries have approved their product ITULAZAX® for treating tree pollen allergy in children aged five to 17. It details the regulatory procedure (type II variation), mentions clinical trial data (TT-06 study), and includes quotes from management and contact information for Investor Relations and Press. This type of announcement, focusing on a specific regulatory milestone or product approval, is best classified as a general Regulatory Filing (RNS) or potentially an announcement related to product development/market access, but RNS serves as the best fit for general, non-financial, non-management change regulatory news that doesn't fit a more specific category like ER, 10-K, or DIV. Given the content is a specific regulatory approval announcement, RNS is the most appropriate general regulatory category.
2025-04-23 Danish
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document announces the approval of a regulatory filing for the drug ITULAZAX® for pediatric use across 17 EU countries. It details the regulatory procedure (type II variation), mentions the supporting clinical trial (TT-06), and discusses future market introductions. This is a specific announcement regarding regulatory progress and clinical data validation, not a comprehensive annual report (10-K), an earnings release (ER), or a general investor presentation (IP). Since it is a specific announcement about regulatory action and clinical trial results validation, it fits best under the general 'Regulatory Filings' category (RNS) as it is a formal communication of a regulatory event, although it contains elements of R&D/Product news. Given the options, RNS serves as the best fit for a specific regulatory approval announcement that isn't a standard financial report or a management change.
2025-04-23 English
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document is a short announcement from ALK regarding the approval of ITULAZAX® for treating tree pollen allergy in children across 17 EU countries. It details the regulatory process (type II-variation procedure), mentions clinical trial data (TT-06 study), and provides contact information for Investor Relations and Press. Crucially, the document ends with a section titled "Vedhæftet fil" (Attached file) which includes a link to download the actual company announcement. According to Rule #2 (The 'MENU VS MEAL' Rule), when a document is short and announces that a report has been published or provides a link to download it, it should be classified as a Report Publication Announcement (RPA). This is not the full financial report (10-K or IR) or a transcript (CT), but rather the announcement of the news itself.
2025-04-23 Danish
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document announces the approval of a regulatory filing for the drug ITULAZAX® in 17 EU countries. It details the clinical trial data used for the submission and mentions that the approval is based on a 'European regulatory filing' and a 'type II variation procedure'. This is a specific corporate announcement regarding regulatory progress, not a comprehensive financial report (like 10-K or IR) or a general earnings release (ER). Since it is a specific announcement about regulatory progress that doesn't fit perfectly into the other categories (like DIRS, DIV, or M&A), and it is a formal corporate communication, it best fits the general 'Regulatory Filings' category (RNS) as a fallback for specific, non-financial regulatory news, or potentially a Legal/Regulatory update, but RNS is the most appropriate general regulatory announcement category here, as it is not a legal proceeding (LTR). Given the context of a press release announcing regulatory success, RNS is the most suitable general classification.
2025-04-23 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.